PTCT - JPM 2025- 1.13.25 -vF.pdf

1、PTC Therapeutics JP Morgan 20251Matthew B.Klein,MDCEOPTC Therapeutics 2025Pam and Kelsey living with PKUPTC Therapeutics JP Morgan 2025PTC Therapeutics JP Morgan 2025PTC Therapeutics JP Morgan 2025PTC Therapeutics JP Morgan 20253PTC Therapeutics JP Morgan 2025This presentation contains forward-looki

2、ng statements within the meaning of The Private Securities Litigation Reform Act of 1995.All statements contained in this presentation,other than statements of historic fact,are forward-looking statements,including statements with respect to 2025 total revenue guidance and 2025 operating expenditure

3、 guidance and statements regarding:the future expectations,plans and prospects for PTC,including with respect to the expected timing of clinical trials and studies,availability of data,regulatory submissions and responses,commercialization and other matters with respect to its products and product c

4、andidates;PTCs strategy,future operations,future financial position,future revenues,projected costs;and the objectives of management.Other forward-looking statements may be identified by the words,guidance,plan,anticipate,believe,estimate,expect,intend,may,target,potential,will,would,could,should,co

5、ntinue,and similar expressions.PTCs actual results,performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties,including those related to:the outcome of pricing,coverage and reimburseme

6、nt negotiations with third party payors for PTCs products or product candidates that PTC commercializes or may commercialize in the future;PTCs ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil,Russia,the European Economic Area(EEA)and other regions,i